Table 1. Summary of tumor tissue morphologic assessment.

Pathology Evaluation	Mitosis (HPF)	Necrosis	Inflammation	Microscopy General
Treatment Groups
Intact LLC – WT host Saline Injection	22.5 ± 4.5	6 ± 1.4	None	Large, highly proliferative, aggressive tumors, no necrosis
p75KD/LLC – WT host Saline Injection	22.3 ± 2.2	13.3 ± 6	None	Large, highly proliferative, aggressive, mostly viable tumors, insignificant focal apoptosis and necrosis
Intact LLC – WT host mrTNF Injection	43.5 ± 21	36.5 ± 4.6	Very mild focal	Large tumor, highly mitotic – up to 106 mitotic bodies/HPF, aggressive, mild apoptosis and necrosis, mostly viable
p75KD/LLC – WT host mrTNF Injection	18 ± 10.4	44.7 ± 13.5	Mild to Moderate	No tumor left in 1/3 of the samples, while 2/3 of tumors are 40–60% necrotic, with signs of acute and chronic inflammation

Morphological findings in four treatment groups including - mitotic counts, area of necrosis, inflammatory infiltrate and major morphological findings. To avoid inter-observer variability a single clinical pathologist who was blinded to treatment conditions had evaluated H&E and PAS stained slides for all four treatment groups.